GAC Motor’s display of its globalization drive and the latest models at the North American International Auto Show ticked all the right boxes as the leading automotive manufacturer in China built up intimacy with international customers, dealers and business partners.
GAC put its best foot forward in reinforcing its ambitions of making cars for the world as it shed the light on its go–outbound campaign during the international auto exhibition in Detroit that concluded on January 25, 2015.
“After meticulous planning and careful studies, we start to create our own brands by adopting international standards,” said Wu Song, general manager of GAC Motor. “We are confident that GAC Motor can churn out world-class vehicles to compete in the international market.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7447151-gac-motors-detroit-auto-show/
On November 17th, catch John Mayer on Fuse live from the landmarked Beacon Theatre in New York City. Be the first to see world premiere performances from his brand new album
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
Do science and religion conflict? Is there disagreement between science and spirituality? It turns out there is no conflict. The apparent conflict is because, till now, the metaphors of ancient texts such as the Bible, Talmud, and ancient Yoga Literature, had not been rigorously studied and compared to cutting edge scientific discoveries. Some of these studies have been reviewed by scientists and published in three international peer-reviewed scientific journals. Sanjay's research on the new agreements between spirituality and science is the first ever to get published in such high-ranking journals.
By Sanjay C. Patel, Author of GOD IS REAL - The Stunning New Convergence of Science and Spirituality. Visit: http://www.SanjayCPatel.com
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
The Department of Veterans Affairs will recognize 2012 National VA Research Week April 23 – 27. This year’s theme, “Caring for Veterans Through Discovery & Collaboration,” will mark a week that celebrates the contributions of Veterans who make research possible by participating in VA research studies as well as VA investigators and collaborators.
John P. Holdren, PhD, Director of the White House Office of Science and Technology Policy and Assistant to the President, will be a featured speaker at VA’s Research Week Forum April 26. The Forum, to be held at VA Central Office in Washington D.C., is part of the Department’s annual Research Week celebration. Dr. Joel Kupersmith, Chief Research and Development Officer, will provide opening remarks and serve as Forum moderator.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52323-deka-arm-veterans-2012-va-national-research-week
A study conducted by researchers from the University of L’Aquila in Italy and Mars, Incorporated provides compelling new evidence that the regular consumption of dietary cocoa flavanols may improve cognitive function in elderly subjects with early memory decline. Just published online in the journal Hypertension, this current study significantly advances understanding of the benefits of flavanols by specifically exploring the impact of regular cocoa flavanol consumption on cognitive function in a population with Mild Cognitive Impairment (MCI). Previous research has suggested that the benefits of cocoa flavanols could extend to the brain. However, these studies were either only short-term or did not demonstrate a consistent cognitive benefit. This unique study addresses this gap and provides important insights into the possibility of slowing or even reversing cognitive declines associated with aging through consumption of these natural compounds.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/marsincorporated/56580/
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
Did you know central Wisconsin is the ideal place to cultivate ginseng, an herb prized by Chinese and other Asian cultures for its health benefits? Neither did first-generation immigrant Paul Hsu. After he figured it out, he founded Hsu Ginseng Enterprises, which continually sets the standards for quality and purity as the global leader in the ginseng industry.
Meanwhile, Paul’s son, Will, grew up and went on to college. He earned his degree in finance at the University of Wisconsin’s School of Business with additional majors in Chinese language and East Asian studies. After graduation, Will accepted a position at General Mills, where he worked for more than a decade. During that time, the company sponsored his MBA at Harvard Business School.
Two seemingly divergent paths for father and son, but a question kept persisting for Will that kept those two paths from completely separating: “Are you going to take over the family business?”
To view the multimedia release go to:
http://www.multivu.com/players/English/74221515-northwestern-mutual-hsu-ginseng-enterprises/
